Mohsin Ali, MD
Sleep Medicine · Watertown, NYNPI 1093912909
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.8% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,494 and has fallen 92.5% since, to $112 in 2025.
Across 151 payments — averaging $17.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$385
- Genentech USA, Inc.$252
- Lilly USA, LLC$195
- Novartis$193
- Biogen$189
- AstraZeneca$149
- plus $1K from 31 others
What the payments were for
- Food & beverage$2,48993%
- Education$1927%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 18 | $385 |
| Genentech USA, Inc. | 15 | $252 |
| Lilly USA, LLC | 15 | $195 |
| Novartis | 14 | $193 |
| Biogen | 13 | $189 |
| AstraZeneca | 4 | $149 |
| AbbVie(2 entities) | 7 | $115 |
| UCB, Inc. | 5 | $100 |
| Amgen | 4 | $99 |
| Livanova USA, Inc. | 4 | $82 |
| EMD Serono, Inc. | 5 | $78 |
| Supernus Pharmaceuticals, Inc. | 6 | $68 |
| Sunovion Pharmaceuticals Inc. | 5 | $65 |
| Sanofi | 3 | $62 |
| Kyowa Kirin, Inc. | 2 | $51 |
| Pfizer | 2 | $51 |
| Eisai Inc. | 2 | $47 |
| Neurelis, Inc. | 2 | $44 |
| Avanir Pharmaceuticals, Inc. | 3 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $37 |
| Mallinckrodt Enterprises LLC | 2 | $35 |
| Lundbeck LLC | 1 | $33 |
| CSL Behring | 2 | $31 |
| Grifols USA, LLC | 1 | $30 |
| Neurocrine Biosciences, Inc. | 2 | $29 |
| Strongbridge US Inc. | 1 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Abiomed | 1 | $21 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Merz North America, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Harmony Biosciences LLC | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| SK Life Science, Inc. | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
How this compares
$2,681 in reported general payments places this provider in the 65th percentile of 81 sleep medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 23 | $159,423 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 16 | $143,222 |
| Aimovig AutoinjectorErenumab-Aooe | 66 | $86,141 |
| BanzelRufinamide | 13 | $80,298 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 16 | $79,860 |
| Glatiramer Acetate | 21 | $64,355 |
| Emgality PenGalcanezumab-Gnlm | 36 | $43,018 |
| BotoxOnabotulinumtoxina | 36 | $34,323 |
| Teriflunomide | 20 | $32,180 |
| LamictalLamotrigine | 21 | $31,836 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 22 | $27,258 |
| RytaryCarbidopa/Levodopa | 14 | $26,956 |
| Lacosamide | 108 | $13,285 |
| Memantine Hcl | 475 | $12,382 |
| Pregabalin | 321 | $11,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $31 | $159,42323 claims |
| Grifols USA, LLCGamunex-C | $30 | $143,22216 claims |
| Eisai Inc.Banzel | $47 | $80,29813 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $17 | $79,86016 claims |
| AbbVieBotox | $115 | $34,32336 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $20 | $30,01760 claims |
| PfizerDilantin | $51 | $5,90149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 81 sleep medicine providers in New York.
Other sleep medicine in Watertown
- David RapoportNew York$313K
- Ofer JacobowitzNew York$141K
- Qanta AhmedMineola$83K
- Andrew WestwoodNew York$82K
- Omar BurschtinNew York$71K
- Maha AhmadNew York$38K
- Daniel BaroneNew York$37K
- James ChmielE. Amherst$30K
- Vincent GrbachNew York$21K
- Andrew VargaNew York$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.